'+
'| • '+heading+' |
| '+
''+
' |
'); } function hiLite(imgDocID,imgObjName) { document.images[imgDocID].src = eval(imgObjName + ".src"); } function showStatus(toshow) { window.status = toshow; } function checkChoose() { if (document.choose.ticker.value == "") { alert("Please enter symbols before clicking the go button"); return false; } else return true; } function popJT(url,name){ var xwid = screen.width; xwid = xwid - 10; javaticker = window.open(url,name,'width='+xwid+',height=100,resizable=yes,scrollbars=no,toolbar=no,location=no,directories=no,status=yes,menubar=no'); javaticker.opener.name="opener"; //javaticker.moveTo(0,30); } var allow = 0; var ref = ""+location; if ((ref.indexOf("cryptocurrencieschannel.com") > 0) || (ref.indexOf("cefchannel.com") > 0) || (ref.indexOf("bdcinvestor.com") > 0) || (ref.indexOf("tickertech.com") > 0) || (ref.indexOf("xxxx:") > 0) || (ref.indexOf("javascript:") > 0) || (ref.indexOf("filseclab.com") > 0) || (ref.indexOf("msnscache.com") > 0) || (ref.indexOf("toolbar.google.com") > 0) || (ref.indexOf("etfchannel.com") > 0) || (ref.indexOf("marketnewsvideo.com") > 0) || (ref.indexOf("news.google.com") > 0) || (ref.indexOf("dividendchannel.com") > 0) || (ref.indexOf("www.google.com") > 0) || (ref.indexOf("energystockchannel.com") > 0) || (ref.indexOf("metalschannel.com") > 0) || (ref.indexOf("portfoliochannel.com") > 0) || (ref.indexOf("canadastockchannel.com") > 0) || (ref.indexOf("theonlineinvestor.com") > 0) || (ref.indexOf("investhelp.com") > 0) || (ref.indexOf("preferredstockchannel.com") > 0) || (ref.indexOf("stockoptionschannel.com") > 0) || (ref.indexOf("holdingschannel.com") > 0) || (ref.indexOf("tickertech.net") > 0) || (ref.indexOf("historicalstockprice.com") > 0) || (ref.indexOf("splithistory.com") > 0) || (ref.indexOf("stocksplithistory.com") > 0) || (ref.indexOf("google.c") > 0) || (ref.indexOf("208.71.46.190") > 0) || (ref.indexOf("search.yahoo") > 0) || (ref.indexOf("sharesoutstandinghistory.com") > 0) || (ref.indexOf("marketcaphistory.com") > 0) || (ref.indexOf("ytdreturn.com") > 0) || (ref.indexOf("averageannualreturn.com") > 0) || (ref.indexOf("redinews.com") > 0) || (ref.indexOf("technicalanalysischannel.com") > 0) || (ref.indexOf("stockdma.com") > 0) || (ref.indexOf("stockrsi.com") > 0) || (ref.indexOf("stockmacd.com") > 0) || (ref.indexOf("topdividends.com") > 0) || (ref.indexOf("monthlydividendpayingstocks.com") > 0) || (ref.indexOf("nextearningsdate.com") > 0) || (ref.indexOf("pastearnings.com") > 0) || (ref.indexOf("historicalperatio.com") > 0) || (ref.indexOf("historicalearnings.com") > 0) || (ref.indexOf("webcache.googleusercontent.com") > 0)) { allow = 1; } function ShowTTIPage() { if (allow) { document.write('\n'); } if (allow) { document.write('
\n'); } if (allow) { document.write('| 4/25 - 4:30 PM \; \; | \n'); } if (allow) { document.write('Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update | \n'); } if (allow) { document.write('
| 4/19 - 4:30 PM \; \; | \n'); } if (allow) { document.write('Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | \n'); } if (allow) { document.write('
| 4/15 - 7:02 AM \; \; | \n'); } if (allow) { document.write('Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102 | \n'); } if (allow) { document.write('
| 4/12 - 4:23 PM \; \; | \n'); } if (allow) { document.write('Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome | \n'); } if (allow) { document.write('
| 4/12 - 8:00 AM \; \; | \n'); } if (allow) { document.write('Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting | \n'); } if (allow) { document.write('
| 3/22 - 4:00 PM \; \; | \n'); } if (allow) { document.write('Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | \n'); } if (allow) { document.write('
| 3/15 - 12:47 PM \; \; | \n'); } if (allow) { document.write('Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical, Inc. to Contact Law Firm | \n'); } if (allow) { document.write('
| 2/27 - 4:30 PM \; \; | \n'); } if (allow) { document.write('Ultragenyx to Participate at Investor Conferences in March | \n'); } if (allow) { document.write('
| 2/23 - 4:05 PM \; \; | \n'); } if (allow) { document.write('Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | \n'); } if (allow) { document.write('
| 2/15 - 4:01 PM \; \; | \n'); } if (allow) { document.write('Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update | \n'); } if (allow) { document.write('
| 2/8 - 4:00 PM \; \; | \n'); } if (allow) { document.write('Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update | \n'); } if (allow) { document.write('
| 2/6 - 8:00 AM \; \; | \n'); } if (allow) { document.write('Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA) | \n'); } if (allow) { document.write('
| 2/5 - 4:05 PM \; \; | \n'); } if (allow) { document.write('Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome | \n'); } if (allow) { document.write('
| 1/25 - 4:05 PM \; \; | \n'); } if (allow) { document.write('Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease | \n'); } if (allow) { document.write('
| 1/19 - 4:00 PM \; \; | \n'); } if (allow) { document.write('Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | \n'); } if (allow) { document.write('
| 1/7 - 11:00 AM \; \; | \n'); } if (allow) { document.write('Ultragenyx Reports Preliminary 2023 Revenue\; Guidance for 2024 Revenue and Cash Usage\; Pipeline Updates and 2024 Milestones | \n'); } if (allow) { document.write('
| 1/4 - 8:03 AM \; \; | \n'); } if (allow) { document.write('Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH) | \n'); } if (allow) { document.write('
| 1/3 - 8:00 AM \; \; | \n'); } if (allow) { document.write('Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome | \n'); } if (allow) { document.write('
| 1/2 - 4:05 PM \; \; | \n'); } if (allow) { document.write('Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference | \n'); } if (allow) { document.write('
 | |
| \n'); } if (allow) { document.write(' | |
If you reached this page'+
' after attempting to place a TickerTech.com product onto your web page, go no further; you must sign up as a'+
' paying client. For pricing information please visit our products page, email '+
' services@tickertech.com, or give us a call at 1-866-515-2082.'+
' '+
'